Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ FGFR4 Monoclonal Antibody (4FR6D3)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA528550
Description
This antibody reacts with an extracellular epitope of CD334, the fibroblast growth factor receptor 4, which is an approximately 88 kDa receptor tyrosine kinase expressed in variety of tissues.
FGFR4 is a member of the FGFR family of receptor tyrosine kinases. This family is known to regulate a host of cellular functions including angiogenesis, mitogenesis, osteogenesis, myogenesis, carcinogenesis, cellular differentiation, and tissue repair after injury. The FGFR family has also been implicated in a number of diseases including cancer, rheumatoid arthritis, and diabetic retinopathy. FGFR4 is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. FGFR4 plays a role in postnatal lung development and may be involved in the development of skeletal muscle cell lineages.
Specifications
FGFR4 | |
Monoclonal | |
1 mg/mL | |
PBS with 15mM sodium azide; pH 7.4 | |
P22455 | |
Fgfr4 | |
full length human CD334- transfected NIH 3T3 cells. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 κ |
Flow Cytometry, Immunocytochemistry | |
4FR6D3 | |
Unconjugated | |
Fgfr4 | |
CD334; CTLA-2-beta protein; FGF Receptor; FGF Receptor 4; FGFR; Fgfr4; FGFR-4; Fibroblast growth factor receptor 4; fibroblast growth factor receptor 4 16 minus form; hydroxyaryl-protein kinase; JTK2; MGC20292; Mpk-11; protein-tyrosine kinase; protein-tyrosine kinase receptor MPK-11; TKF; tyrosine kinase related to fibroblast growth factor receptor; tyrosylprotein kinase | |
Mouse | |
Protein A | |
RUO | |
2264 | |
4°C, do not freeze | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction